ECE2018 Poster Presentations: Adrenal and Neuroendocrine Tumours Endocrine tumours and neoplasia (34 abstracts)
Achievement of therapeutic mitotane concentrations in management of advanced adrenocortical cancer: a single centre experience in 47 patients
Mohamed Bakhit 1 , Benjamin C Whitelaw 1 , Jackie Gilbert 1 , Patsy Coskeran 1 , Salvador Diaz-Cano 2 , David R Taylor 3 , Norman T Taylor 3 , Lea Ghatore 3 , Dylan Lewis 4 , Gillian Vivian 5 , Debashis Sarker 6 , Paul Ross 6 , Laura May Davis 1 , Jennifer Clough 1 , Johnathan G Hubbard 7 , Gabriele Galata 7 , Andreas Prachalias 8 , Klaus-Martin Schulte 7 & Simon J B Aylwin 1
1Department of Endocrinology, King’s College Hospital, London, UK; 2Department of Histopathology, King’s College Hospital, London, UK; 3Department of Clinical Biochemistry (Viapath), London, UK; 4Department of Radiology, King’s College Hospital, London, London, UK; 5Department of Nuclear Medicine, King’s College Hospital, London, UK; 6Department of Medical Oncology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK; 7Department of Endocrine Surgery, King’s College Hospital, London, UK; 8Department of Hepato-Pancreatico-Biliary Surgery, King’s College Hospital, London, UK.
Introduction: Multi-modal therapy for adrenocortical carcinoma (ACC) includes surgery, therapy with the adrenolytic agent mitotane and systemic chemotherapy. Achievement of therapeutic mitotane concentrations (≥14 mg/l) has been related to improved outcomes.
Aim: To evaluate the effectiveness of a defined* high dose protocol mitotane therapy in patients with advanced ACC (stages III and IV).
Methods: Review of patients presenting to KCH with stage III or IV ACC and the mitotane concentration achieved through the Lysosafe monitoring service.
Results: N=57 patients were referred and first diagnosed with ACC (2008-17) of whom 44 patients had stage III or IV disease at diagnosis and were managed actively with surgery and/or mitotane therapy. 40/44 patients underwent surgical resection of the primary tumour;11/22 patients with stage IV disease subsequently received systemic chemotherapy [10 patients received a combination of etoposide, doxorubicin and cisplatin (EDP) and 1 patient received a combination of carboplatin and etoposide]. 38/44 patients were initiated on mitotane therapy. The median overall survival of patients with stage IV disease was 25.3 months. The median survival for stage III has not been reached. An additional 9 patients had prior management, including surgery, elsewhere and were referred for mitotane initiation. A total of 47 patients were therefore included in the mitotane pharmacokinetic analysis. Six patients were excluded: 3 patients died shortly after mitotane initiation, 1 patient withdrew due to a severe reaction and 2 patients had not completed 12 weeks therapy at the time of submission. Of the remaining 41 patients, 33 commenced the ‘high dose’ protocol and the remainder the ‘low dose’ protocol. For patients on the high dose protocol, 25/33 (76%) reached a mitotane concentration ≥14 mg/l within 12 weeks of initiation of therapy, compared to 3 patients from the low dose protocol group (P=0.084). In the high dose protocol group, 21 patients (84%) maintained therapeutic drug concentrations in ≥50% of the subsequent follow-up samples and 12 patients (48%) maintained therapeutic drug concentrations in ≥75% of subsequent samples.
Conclusion: The use of high dose protocol mitotane therapy is a successful strategy to achieve and maintain therapeutic drug concentrations when treating patients with advanced ACC (stages III and IV). In combination with an assertive surgical approach and optimal chemotherapy, this has resulted in outcomes that compare favourably (median OS 25.5 months in stage IV disease) with previously published series which describe a median OS <12 months.
*Kerkhofs JCEM 2013
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more